Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2021-02-15 Regulatory Filings
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1939 characters) and contains the header 'RNS Number : 0917P' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, immediate operational announcement. This type of short, time-sensitive regulatory update that doesn't fit into the major financial reporting categories (like 10-K, ER, IR) is best classified under the general regulatory announcement category, RNS, as per the definitions and the 'MENU VS MEAL' rule suggesting short announcements default to RPA or RNS.
2021-02-15 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1922 characters) and contains the header 'RNS Number : 0911P' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security, which is a specific operational update related to trading mechanisms, not a comprehensive financial report or a standard regulatory filing like 10-K or ER. Since it is a short, specific regulatory announcement that doesn't fit the other defined categories (like DIV, DIRS, or ER), it falls best under the general regulatory announcement category, RNS.
2021-02-15 English
Group of companies' accounts made up to 2020-04-30
Regulatory Filings
2021-02-10 English
Update on SCIB2 clinical development partnership
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 7830N' and is dated '03 February 2021'. It contains standard boilerplate language indicating it is a regulatory announcement distributed via RNS, stating, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' The content details a business update—the termination of a clinical development partnership for the SCIB2 vaccine. This is a material, non-financial announcement released through the official regulatory news service. Since it is a general regulatory announcement that doesn't fit specific categories like Director's Dealing (DIRS), Dividend (DIV), or Earnings Release (ER), the most appropriate classification is the general regulatory filing category.
2021-02-03 English
Interim Results for the 6 months ended 31 Oct 2020
Interim / Quarterly Report Classification · 95% confidence The document is an 'Interim Results' announcement for Scancell Holdings Plc for the 6-month period ended 31 October 2020. It contains financial highlights, a Chairman's statement, and operational updates. While it is a report, it is presented in the format of an RNS (Regulatory News Service) announcement, which is the standard way UK-listed companies release their interim results to the market. It includes the RNS number, company details, and a summary of financial performance, fitting the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis. H1 2020
2021-01-29 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1922 characters) and contains the header 'RNS Number : 1803K' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Price Monitoring Extension' which is a procedural update related to trading mechanisms, not a comprehensive financial report or a specific corporate action like a dividend or management change. Since it is a general regulatory announcement distributed via the RNS system that doesn't fit into the more specific categories (like 10-K, ER, DIV, etc.), it defaults to the general regulatory filing category.
2020-12-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.